SUBSCRIBE: Print / eNewsletter
CLL Patients Willing to Trade Some Drug Efficacy for Reduced Side Effects
Although a longer progression-free survival is of high importance to CLL patients, a reduced risk of serious adverse events might be worth a tradeoff for some efficacy.
Adding Brentuximab to BEACOPP Promising in Relapsed Hodgkin Lymphoma
Use of two BEACOPP regimens that incorporated brentuximab resulted in improved rates of complete response and complete remission at the end of treatment.
Integrating Genetics, MRD Improves Risk Stratification in Childhood ALL
Integrating genetic risk factors with minimal residual disease improves the accuracy of risk stratification for children with acute lymphoblastic leukemia.
Abnormal Liver Function Linked to Survival in CLL
About one in every 25 patients with chronic lymphocytic leukemia had abnormal liver function tests, and one in four developed liver dysfunction within 10 years, according to the results of a retrospective study.
Breast Implants Linked to Anaplastic Large-Cell Lymphoma
In this interview we discuss the link between breast implants and anaplastic large-cell lymphoma, a rare type of T-cell lymphoma.
Crizotinib Produced Robust Response in ALK-Positive Pediatric Lymphoma
Pediatric patients with ALK-positive anaplastic large cell lymphomas and inflammatory myofibroblastic tumors had strong responses to treatment with crizotinib.
FDA Approves New Acute Lymphoblastic Leukemia Treatment
The FDA has approved inotuzumab ozogamicin (Besponsa) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Significant Portion of Pediatric NHL Cases Occur in Transplant Recipients
Pediatric solid organ transplant recipients account for about 3% of diagnosed pediatric non-Hodgkin lymphoma cases in the United States.
ATO Consolidation in Pediatric APL Allows for Reduced Anthracycline Dose
Arsenic trioxide consolidation was well tolerated in pediatric patients with acute promyelocytic leukemia and allowed for significant reductions in cumulative anthracycline doses.
CML Blast Phase Outcomes Remain Poor in TKI Era, Prognostic Factors Identified
Patients with chronic myeloid leukemia in the blast phase pose a significant therapeutic challenge and have poor survival, even in the tyrosine kinase inhibitor era, according to a new study.